Abbvie Inc.

Abbott Laboratories Corporation

Abbyie Inc.

Abbvie Bahamas Limited

Michael L Curtin

Michael Michaelides

Howard Robin Heyman

Robin R Frey

Richard F Clark

Todd M Hansen

Steven K Davidsen

Bryan K Sorensen

Kenton L Longenecker

Zhiqin Ji

Marina Pliushchev

Ramzi Farah Sweis

Carol K Wada

Alan S Florjancic

James H Holms

George A Doherty

Gavin C Hirst

Kevin R Woller

Paul Rafferty

David J Calderwood

Yan Guo

Douglas H Steinman

Kelly Mullen

Andrew Burchat

Peter Hrnciar

Heather M Davis

Lianhong Xu

Patrick Betschmann

Melanie A Muckey

Anil Vasudevan

George S Sheppard

Jianchun Gong

Yujia Dai

Neil Wishart

Augustine Osuma

Michael R Michaelides

Andy Judd

Thomas Dale Penning

Andrew J Souers

Zhi-Fu Tao

Helmut Mack

Milan Bruncko

Lee Daniel Arnold

Xiaohong Song

Kristine E Frank

James B Summers, Jr

Keith W Woods

Joseph F Dellaria, Jr

Robert B Garland

Yunsong Tong

Ying Wang

Chunqiu Lai

Biqin C Li

Justin D Dietrich

Hongyu H Zhao

Anthony Mastracchio

George M Carrera, Jr

Huan-Qiu Li

Guidong Zhu

Chris Tse

H Robin Heyman

Rajeev Goswami

Omar J Shah

Jamie R Stacey

Jamie R Giesler

Madhu Babu Dabbeeru

Nathan S Josephsohn

Omprakash Reddy Iguturi

Roberto M Risi

Juliem Miyashiro

Mariazel Torrent

William J Mcclellan

Howard R Heyman

Andrew F Burchat

Compounds having a structure of Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein A, A, A, A, A, n, and m are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various EED-related conditions or diseases, including cancer, by administration of such compounds are also provided.

Indane inhibitors of EED and methods of their use

Disclosed are compounds of Formula (IIa), wherein R, R, R, R, R, R, R, and Rare as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa).

Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors

Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.

NAMPT inhibitors

Disclosed are 1,3-dihydro-2H-isoindole compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of using the compounds to treat diseases during which NAMPT is expressed, e.g., cancer, metabolic disorders, and inflammatory disorders. Disclosed are 1,3-dihydro-2H-isoindole compounds which inhibit the activity of ROCK, compositions containing the compounds and methods of using the compounds to treat diseases during which ROCK is expressed, e.g., cancer, cardiovascular disorders, and inflammatory disorders.

NAMPT and rock inhibitors

Compounds that inhibit protein kinases such as Aurora-kinases and the VEGFR and PDGFR families of kinases, with an improved safety profile due to low CYP3A4 inhibition, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.

Thieno[3,2-C]pyridine kinase inhibitors with improved CYP safety profile

The present disclosure is directed to novel compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are as defined herein. The compounds of Formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, Crohn's disease, psoriasis and asthma.

[object Object]

4-Amino-N-[3-(diethylamino)propyl]-3-(4-{[(3-fluorophenyl)carbamoyl]amino}phenyl)thieno[3,2-c]pyridine-7-carboxamide which inhibits protein kinases such as Aurora-kinases and the VEGFR and PDGFR families of kinases, with an improved aqueous solubility profile, compositions containing 4-amino-N-[3-(diethylamino)propyl]-3-(4-{[(3-fluorophenyl)carbamoyl]amino}phenyl)thieno[3,2-c]pyridine-7-carboxamide and methods of treating diseases using 4-amino-N-[3-(diethylamino)propyl]-3-(4-{[(3-fluorophenyl)carbamoyl]amino}phenyl)thieno[3,2-c]pyridine-7-carboxamide are disclosed.

Kinase inhibitor with improved solubility profile

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, A, A, A, X and Y are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as aurora and KDR.

Pyrimidine inhibitors of kinases

Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

Thienopyridine and furopyridine kinase inhibitors

Growing community of inventors

Pleasant Prairie, WI, United States of America

Michael L Curtin